The Barcelona Stroke Registry was established to collect clinical data of hospitalized patients with stroke, in order to study their clinical characteristics and outcome. Data were collected over a 17-year period in 3,577 consecutive patients with first-ever stroke admitted to a stroke unit in two university hospitals in the city of Barcelona (Catalonia, Spain). Patients were generally admitted within 48 h from stroke onset, were evaluated by a neurologist, and clinical data were collected using a standardized protocol. All subjects underwent computerized tomography (CT) examination. Data on the 3,577 patients revealed the following stroke subtypes: cerebral infarction (81%), corresponding to the varieties of atherothrombotic (39.5%), cardioembolic (17.5%), lacunar (11%), unusual (5%), or unknown (8%); and cerebral hemorrhage. We analyzed age distribution (mean age 66 years); risk factors (the most frequent being hypertension, present in 54% of cerebral infarctions and in 65% of hemorrhages); clinical manifestations (the most salient being abrupt onset in one half of the cases; high frequency of decreased consciousness in cardioembolic infarction; headache, seizures and nuclear palsy in ‘unusual’ cerebral infarctions; vomiting and coma in hemorrhage); localizations by vascular territories; mechanisms of the various stroke subtypes; complications (present in one third of patients, with a mortality of 14%), and outcome. Two out of 3 hospitalized stroke patients are first-ever stroke sufferers. Neuroimaging shows a cerebral infarct in 86.5% of cases. Clinical and laboratory investigations cannot determine the mechanism of 8% of infarcts and of 23% of hemorrhages. The high frequency of medical complications, mortality, and disability highlights the need to establish stroke units and stroke registries in order to perform further research into the diagnosis and management of patients with cerebrovascular disease.

1.
Langhorne P, Williams BO, Gilchrist W, Howle K: Do stroke units save lives? Lancet 1993;342:395–398.
2.
Mohr JP: Stroke Data Banks. Stroke 1986;17:171–172.
3.
Brainin M: Overview of stroke data banks. Neurepidemiology 1994;13:250–258.
4.
Martí-Vilalta JL: Enfermedades vasculares cerebrales: Estudio clínico prospectivo. Sant Pau 1984;5:9–14.
5.
Arboix A, Massons J, Oliveres M, Garcia L, Titus F: Registro de patología cerebrovascular de La Alianza Hospital Central de Barcelona. Med Clin (Barc) 1993:101:281–285.
6.
Ad Hoc Committee: A Classification and Outline of Cerebrovascular Diseases. II. Stroke 1975;6:565–616.
7.
Martí-Vilalta JL, Matías-Guiu J: Nomenclatura de las enfermedades vasculares cerebrales. Neurologia 1987;2:166–175.
8.
Bogousslavsky J, VanMelle G, Regli F: The Lausanne Stroke Reigstry: Analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083–1092.
9.
Moulin T, Tatu L, Crépin-Leblond T, Chavot D, Bergès S, Rumbach L: The Besançon Stroke Registry: An acute stroke registry of 2,500 consecutive patients. Eur Neurol 1997;38:10–20.
10.
Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB: The Stroke Data Bank: Design, methods and baseline characteristics. Stroke 1988;19:547–554.
11.
Spitzer K, Becker V, Thie A, Kunze K: The Hamburg Stroke Data Bank: Goals, design and preliminary results. J Neurol 1989;236:139–144.
12.
Mohr JP, Caplan LR, Melski JW, Goldstein RJ, Duncan GW, Kistler JP, Pessin MS, Bleich HL: The Harvard Cooperative Stroke Registry: A prospective registry. Neurology 1978;28:754–762.
13.
Alter M, Christoferson L, Resch J, Myers G, Ford J: Cerebrovascular disease: Frequency and population selectivity in an upper midwestern community. Stroke 1970;1:454–465.
14.
Ostfeld AM, Skekelle RB, Klawans H, Tufo HM: Epidemiology of stroke in an elderly welfare population. Am J Public Health 1974;64:450–458.
15.
Caplan LR, Hier DB, D’Cruz I: Cerebral embolism in the Michael Reese Stroke Registry. Stroke 1983;14:530–536.
16.
Gross CR, Kase CS, Mohr JP, Cunningham SC, Baker WE: Stroke in South Alabama: Incidence and diagnostic features – a population based study. Stroke 1984;15:249–255.
17.
Bamford J, Sandercock P, Jones L, Warlow Ch: The natural history of lacunar infarction: The Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
18.
Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA: Infarcts of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 1989;25:382–390.
19.
Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finflestein SP: The clinical spectrum of cerebral amyloid angiopathy: Presentations without lobal hemorrhage. Neurology 1993;43:2073–2079.
20.
Kunitz SC, Gross CR, Heyman A, Kase CS, Mohr JP, Price TR, Wolf PA: The pilot stroke data bank: Definition, design and data. Stroke 1984;15:740–746.
21.
Weinfeld FD (ed): The National Survey of Stroke. Stroke 1981;12(suppl 1):1–19.
22.
Becker C, Howard G, McLeroy KR, Yatsu FM, Toole JF, Coull B, Feibel J, Walker MD: Community hospital-based stroke programs: North Carolina, Oregon, and New York. II. Description of Study Population. Stroke 1986;17:285–293.
23.
Wolf PA, Dawber TR, Thomas HE, Colton T, Kannel WB: Epidemiology of stroke. Adv Neurol 1977;16:5–19.
24.
Oxfordshire Community Stroke Project: Incidence of stroke in Oxfordshire: First year’s experience of a community stroke register. BMJ 1983;287:713–717.
25.
Bornstein NM, Aronovich BD, Karepov VG, Gur AY, Treves TA, Oved M, Korczyn AD: The Tel Aviv Stroke Registry. Stroke 1996;27:1770–1773.
26.
Rey A, Martí-Vilalta JL, Arboix A, Abellán MT: Latencia de ingreso hospitalario en patología vascular cerebral. Rev Neurol 1995;23:272–275.
27.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.